Synergistic retention strategy of RGD active targeting and radiofrequency-enhanced permeability for intensified RF & chemotherapy synergistic tumor treatment
Despite gaining increasing attention, chelation of multiple active targeting ligands greatly increase the formation probability of protein corona, disabling active targeting. To overcome it, a synergistic retention strategy of RGD-mediated active targeting and radiofrequency (RF) electromagnetic field-enhanced permeability has been proposed here. It is validated that such a special synergistic retention strategy can promote more poly lactic-co-glycolic acid (PLGA)-based capsules encapsulating camptothecin (CPT) and solid DL-menthol (DLM) to enter and retain in tumor in vitro and in vivo upon exposure to RF irradiation, receiving an above 8 fold enhancement in HeLa retention. Moreover, the PLGA-based capsules can respond RF field to trigger the entrapped DLM to generate solid-liquid-gas (SLG) tri-phase transformation for enhancing RF ablation and CPT release. Therefore, depending on the enhanced RF ablation and released CPT and the validated synergistic retention effect, the inhibitory outcome for tumor growth has gained an over 10-fold improvement, realizing RF ablation & chemotherapy synergistic treatment against HeLa solid tumor, which indicates a significant promise in clinical RF ablation..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Biomaterials - 99(2016), Seite 34-46 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Kun [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1016/j.biomaterials.2016.05.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1980250030 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1980250030 | ||
| 003 | DE-627 | ||
| 005 | 20230514013342.0 | ||
| 007 | tu | ||
| 008 | 160816s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biomaterials.2016.05.014 |2 doi | |
| 028 | 5 | 2 | |a PQ20160815 |
| 035 | |a (DE-627)OLC1980250030 | ||
| 035 | |a (DE-599)GBVOLC1980250030 | ||
| 035 | |a (PRQ)c2074-1d9e8bba9bb72dc08dc99cbc2eedc82fd4ee9cfedac90d514fbf7a0404b178270 | ||
| 035 | |a (KEY)0102422120160000099000000034synergisticretentionstrategyofrgdactivetargetingan | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q DNB |
| 084 | |a BIODIV |2 fid | ||
| 084 | |a 44.09 |2 bkl | ||
| 100 | 1 | |a Zhang, Kun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synergistic retention strategy of RGD active targeting and radiofrequency-enhanced permeability for intensified RF & chemotherapy synergistic tumor treatment |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Despite gaining increasing attention, chelation of multiple active targeting ligands greatly increase the formation probability of protein corona, disabling active targeting. To overcome it, a synergistic retention strategy of RGD-mediated active targeting and radiofrequency (RF) electromagnetic field-enhanced permeability has been proposed here. It is validated that such a special synergistic retention strategy can promote more poly lactic-co-glycolic acid (PLGA)-based capsules encapsulating camptothecin (CPT) and solid DL-menthol (DLM) to enter and retain in tumor in vitro and in vivo upon exposure to RF irradiation, receiving an above 8 fold enhancement in HeLa retention. Moreover, the PLGA-based capsules can respond RF field to trigger the entrapped DLM to generate solid-liquid-gas (SLG) tri-phase transformation for enhancing RF ablation and CPT release. Therefore, depending on the enhanced RF ablation and released CPT and the validated synergistic retention effect, the inhibitory outcome for tumor growth has gained an over 10-fold improvement, realizing RF ablation & chemotherapy synergistic treatment against HeLa solid tumor, which indicates a significant promise in clinical RF ablation. | ||
| 540 | |a Nutzungsrecht: © Elsevier Ltd | ||
| 540 | |a Copyright © 2016 Elsevier Ltd. All rights reserved. | ||
| 700 | 1 | |a Li, Dandan |4 oth | |
| 700 | 1 | |a Li, Pei |4 oth | |
| 700 | 1 | |a Li, Xiaolong |4 oth | |
| 700 | 1 | |a He, Yaping |4 oth | |
| 700 | 1 | |a Bo, Xiaowan |4 oth | |
| 700 | 1 | |a Chen, Hangrong |4 oth | |
| 700 | 1 | |a Xu, Huixiong |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Biomaterials |d Oxford : Elsevier, 1980 |g 99(2016), Seite 34-46 |w (DE-627)130396850 |w (DE-600)603079-8 |w (DE-576)015899578 |x 0142-9612 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2016 |g pages:34-46 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.biomaterials.2016.05.014 |3 Volltext |
| 856 | 4 | 2 | |u http://www.sciencedirect.com/science/article/pii/S0142961216301818 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/27209261 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2411 | ||
| 936 | b | k | |a 44.09 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 99 |j 2016 |h 34-46 | ||